News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
724,964 Results
Type
Article (47168)
Company Profile (392)
Press Release (677404)
Section
Business (213552)
Career Advice (2165)
Deals (36718)
Drug Delivery (94)
Drug Development (83808)
Employer Resources (173)
FDA (16825)
Job Trends (15413)
News (359804)
Policy (33764)
Tag
Academia (2780)
Alliances (52837)
Alzheimer's disease (1289)
Approvals (16745)
Artificial intelligence (153)
Bankruptcy (362)
Best Places to Work (11930)
Biotechnology (285)
Breast cancer (129)
Cancer (1149)
Cardiovascular disease (103)
Career advice (1808)
Cell therapy (256)
Clinical research (66272)
Collaboration (411)
Compensation (203)
COVID-19 (2676)
C-suite (102)
Data (1151)
Diabetes (157)
Diagnostics (6481)
Earnings (86938)
Employer resources (152)
Events (115735)
Executive appointments (323)
FDA (17381)
Funding (374)
Gene therapy (194)
GLP-1 (622)
Government (4503)
Healthcare (19578)
Infectious disease (2765)
Inflammatory bowel disease (114)
Interviews (333)
IPO (16781)
Job creations (3868)
Job search strategy (1542)
Layoffs (441)
Legal (8139)
Lung cancer (180)
Manufacturing (185)
Medical device (13948)
Medtech (13953)
Mergers & acquisitions (20014)
Metabolic disorders (427)
Neuroscience (1578)
NextGen Class of 2024 (6929)
Non-profit (4674)
Northern California (1508)
Obesity (244)
Opinion (200)
Patents (109)
People (59014)
Phase I (20861)
Phase II (29143)
Phase III (21599)
Pipeline (467)
Postmarket research (2628)
Preclinical (9011)
Radiopharmaceuticals (257)
Rare diseases (236)
Real estate (6268)
Regulatory (22449)
Research institute (2528)
Resumes & cover letters (385)
Southern California (1336)
Startups (3896)
United States (14025)
Vaccines (598)
Weight loss (185)
Date
Today (81)
Last 7 days (689)
Last 30 days (3820)
Last 365 days (37238)
2024 (34163)
2023 (41607)
2022 (52878)
2021 (57496)
2020 (56095)
2019 (48939)
2018 (36878)
2017 (34015)
2016 (33707)
2015 (39879)
2014 (33488)
2013 (28735)
2012 (30885)
2011 (31466)
2010 (29394)
Location
Africa (780)
Arizona (202)
Asia (40597)
Australia (6797)
California (3434)
Canada (1303)
China (261)
Colorado (155)
Connecticut (164)
Europe (89767)
Florida (467)
Georgia (124)
Illinois (366)
Indiana (202)
Kansas (101)
Maryland (591)
Massachusetts (2747)
Michigan (174)
Minnesota (284)
New Jersey (978)
New York (980)
North Carolina (756)
Northern California (1508)
Ohio (141)
Pennsylvania (863)
South America (1169)
Southern California (1336)
Texas (485)
Utah (95)
Washington State (378)
724,964 Results for "molecular targeting technologies inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Collaboration
Novartis Inks Potential $2.2B Molecular Glue Deal With Monte Rosa
The Swiss pharma is paying $150 million upfront to gain rights to Monte Rosa’s VAV1-targeting molecular glue degraders, led by a Phase I candidate which holds therapeutic promise for immune-mediated diseases.
October 28, 2024
·
2 min read
·
Tristan Manalac
Lone Star Bio
Molecular Templates, Inc. Provides Interim Update
Molecular Templates, Inc. today provided an update on its clinical-stage programs.
June 3, 2024
·
7 min read
Business
Molecular Templates, Inc. Reports First Quarter 2024 Financial Results and Corporate Update
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action, today reported financial results and business updates for the first quarter of 2024.
May 15, 2024
·
6 min read
Earnings
Biogen Tops Wall Street Expectations for Leqembi, Inks Molecular Glue Deal
Biogen touted strong Q3 sales of its Alzheimer’s drug Leqembi a day after announcing a deal worth up to $1.45 billion with Neomorph to discover and develop molecular glue degraders.
October 30, 2024
·
2 min read
·
Heather McKenzie
Pharm Country
Molecular Targeting Technologies, Inc. to Present EvaThera, Long-Acting Peptide Receptor Radionuclide Therapy Platform, at BioFuture™ 2023
Molecular Targeting Technologies, Inc., is presenting at BioFuture 2023 on Thursday 2:45 PM, Oct 5th, at Lotte New York Palace hotel.
October 5, 2023
·
2 min read
Business
Degron Therapeutics Announces Multi-Target Collaboration and Exclusive License Agreement with Takeda to Discover Molecular Glue Degraders
Degron Therapeutics, the company using its molecular glue-based targeted protein degradation drug-discovery platform to advance human health, announced it has entered into a collaboration and exclusive license agreement with Takeda to discover and develop novel molecular glue degraders for multiple targets in oncology, neuroscience, and inflammation.
May 23, 2024
·
3 min read
Biotech Bay
Alveo’s Portable, Rapid Molecular Diagnostic Platform Proves Unshakable in Rigorous Ruggedness Tests
Alveo Technologies, Inc., a leader in molecular sensing and diagnostics with its proprietary technology platform, announced the results of rigorous testing that demonstrate the ruggedness of its portable molecular testing platform.
June 18, 2024
·
3 min read
Pharm Country
Molecular Targeting Technologies, Inc. and Molecular Theranostics Center of Singapore Receive HSA Approval for Clinical Trial Authorization for EBTATE® in Nasopharyngeal Cancer
Molecular Targeting Technologies, Inc., and its wholly owned subsidiary, Molecular Theranostic Center of Singapore, announced the approval of a Clinical Trial Authorization application by the Health Sciences Authority of Singapore.
August 2, 2023
·
2 min read
Press Releases
BostonGene to Participate in the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
October 23, 2024
·
2 min read
Press Releases
Gain Therapeutics Presents Data at 36ᵗʰ EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2
October 24, 2024
·
4 min read
1 of 72,497
Next